Relmada Therapeutics (RLMD) Tops Q4 EPS by 5c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.28), $0.05 better than the analyst estimate of ($1.33).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• AMC Entertainment prices $200M stock offering to redeem senior notes
• Creatd files Form S-1 and reports Q1 2026 financial results